Total Funding
36
Total FundingPost-IPO Debt raised
Growth Score
pts
Heat Score
3 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
148778
Zogenix develops and commercializes products for the treatment of central nervous system disorders and pain.
Acquired by 
Union Chimique Belge
Mike Smith: EVP, Chief Financial Officer, Head of Corporate DevelopmentPast Role: iPierian, VP, Business Development
Alex Zisson: DirectorPast Role: Thomas, McNerney & Partners, Partner
About the Company
At Zogenix, our core strategy is to develop and commercialize differentiated central nervous system (CNS) and pain therapeutics that can address significant unmet medical needs or overcome limitations of existing products.
We are a specialty pharmaceutical company with two proprietary product candidates in late-stage development for the treatment
of central nervous system disorders and pain. Our lead product candidate, sumatriptan DosePro™, enables needle-free subcutaneous delivery of sumatriptan for the treatment of acute migraine. Our second product candidate, ZX002, is a novel controlled release formulation of hydrocodone for the treatment of chronic pain.
